General Information of DTT (ID: TT1C9K6)

DTT Name Delta-like protein 3 (DLL3) DTT Info
Gene Name DLL3

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Clinical Trial Drug(s)
6 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Rova-T DMNGCAD Small-cell lung cancer 2C25.Y Phase 3 [1]
Tarlatamab DME33OU Small-cell lung cancer 2C25.Y Phase 2 [2]
HPN328 DM1ZHML Small-cell lung cancer 2C25.Y Phase 1/2 [3]
AMG 119 DMKF1O2 Small-cell lung cancer 2C25.Y Phase 1 [4]
AMG 757 DMLYP2N Neuroendocrine cancer 2B72.1 Phase 1 [4]
RG6524 DMT22UV Aggressive cancer 2A00-2F9Z Phase 1 [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Clinical Trial Drug(s)
Molecule Interaction Atlas

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.
3 Clinical pipeline report, company report or official report of Harpoon Therapeutics.
4 Clinical pipeline report, company report or official report of Amgen.
5 Clinical pipeline report, company report or official report of Roche